Annual Operating Expenses
$1.45 B
+$236.10 M+19.41%
31 December 2023
Summary:
Neurocrine Biosciences annual total operating expenses is currently $1.45 billion, with the most recent change of +$236.10 million (+19.41%) on 31 December 2023. During the last 3 years, it has risen by +$541.20 million (+59.38%). NBIX annual operating expenses is now at all-time high.NBIX Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Operating Expenses
$429.30 M
-$3.80 M-0.88%
30 September 2024
Summary:
Neurocrine Biosciences quarterly total operating expenses is currently $429.30 million, with the most recent change of -$3.80 million (-0.88%) on 30 September 2024. Over the past year, it has increased by +$72.90 million (+20.45%). NBIX quarterly operating expenses is now -0.88% below its all-time high of $433.10 million, reached on 30 June 2024.NBIX Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBIX Operating Expenses Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | - | +20.4% |
3 y3 years | +59.4% | +76.0% |
5 y5 years | +162.2% | +174.1% |
NBIX Operating Expenses High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3 years | at high | +59.4% | -0.9% | +76.0% |
5 y | 5 years | at high | +162.2% | -0.9% | +174.1% |
alltime | all time | at high | +8296.5% | -0.9% | >+9999.0% |
Neurocrine Biosciences Operating Expenses History
Date | Annual | Quarterly |
---|---|---|
Sept 2024 | - | $429.30 M(-0.9%) |
June 2024 | - | $433.10 M(+7.6%) |
Mar 2024 | - | $402.50 M(+12.9%) |
Dec 2023 | $1.45 B(+19.4%) | $356.40 M(+2.9%) |
Sept 2023 | - | $346.40 M(-5.8%) |
June 2023 | - | $367.60 M(-3.8%) |
Mar 2023 | - | $382.20 M(+27.0%) |
Dec 2022 | $1.22 B(+33.5%) | $300.90 M(+2.3%) |
Sept 2022 | - | $294.00 M(-7.8%) |
June 2022 | - | $318.70 M(+5.2%) |
Mar 2022 | - | $302.90 M(+24.2%) |
Dec 2021 | $911.40 M(+28.7%) | $243.90 M(-1.4%) |
Sept 2021 | - | $247.30 M(+13.4%) |
June 2021 | - | $218.00 M(+7.8%) |
Mar 2021 | - | $202.20 M(+16.7%) |
Dec 2020 | $708.30 M(+27.8%) | $173.20 M(-4.6%) |
Sept 2020 | - | $181.60 M(+2.4%) |
June 2020 | - | $177.40 M(+0.7%) |
Mar 2020 | - | $176.10 M(+12.5%) |
Dec 2019 | $554.10 M(+36.9%) | $156.60 M(+20.6%) |
Sept 2019 | - | $129.80 M(-8.9%) |
June 2019 | - | $142.50 M(+13.8%) |
Mar 2019 | - | $125.20 M(+21.2%) |
Dec 2018 | $404.70 M(+54.6%) | $103.33 M(+7.8%) |
Sept 2018 | - | $95.88 M(-2.1%) |
June 2018 | - | $97.90 M(-9.0%) |
Mar 2018 | - | $107.58 M(+107.2%) |
Dec 2017 | $261.73 M(+61.2%) | $51.92 M(-21.7%) |
Sept 2017 | - | $66.34 M(+4.4%) |
June 2017 | - | $63.54 M(-20.5%) |
Mar 2017 | - | $79.93 M(+72.8%) |
Dec 2016 | $162.37 M(+42.5%) | $46.25 M(+20.3%) |
Sept 2016 | - | $38.44 M(-8.1%) |
June 2016 | - | $41.83 M(+16.7%) |
Mar 2016 | - | $35.86 M(+16.6%) |
Dec 2015 | $113.97 M(+76.9%) | $30.75 M(-14.2%) |
Sept 2015 | - | $35.84 M(+41.6%) |
June 2015 | - | $25.32 M(+14.8%) |
Mar 2015 | - | $22.06 M(+7.8%) |
Dec 2014 | $64.41 M(+22.5%) | $20.47 M(+21.4%) |
Sept 2014 | - | $16.86 M(+17.4%) |
June 2014 | - | $14.36 M(+12.9%) |
Mar 2014 | - | $12.72 M(+3.8%) |
Dec 2013 | $52.60 M(+1.8%) | $12.26 M(-3.7%) |
Sept 2013 | - | $12.73 M(-8.4%) |
June 2013 | - | $13.90 M(+1.4%) |
Mar 2013 | - | $13.71 M(+2.5%) |
Dec 2012 | $51.69 M(+18.9%) | $13.37 M(+0.3%) |
Sept 2012 | - | $13.32 M(+11.5%) |
June 2012 | - | $11.95 M(-8.5%) |
Mar 2012 | - | $13.06 M(+22.5%) |
Dec 2011 | $43.49 M(-7.9%) | $10.66 M(-4.7%) |
Sept 2011 | - | $11.19 M(+1.2%) |
June 2011 | - | $11.06 M(+4.6%) |
Mar 2011 | - | $10.57 M(-23.3%) |
Dec 2010 | $47.22 M | $13.79 M(+15.1%) |
Sept 2010 | - | $11.98 M(+13.8%) |
Date | Annual | Quarterly |
---|---|---|
June 2010 | - | $10.53 M(-3.6%) |
Mar 2010 | - | $10.92 M(-16.1%) |
Dec 2009 | $54.07 M(-39.4%) | $13.02 M(+25.6%) |
Sept 2009 | - | $10.37 M(-33.7%) |
June 2009 | - | $15.63 M(+3.9%) |
Mar 2009 | - | $15.04 M(-48.8%) |
Dec 2008 | $89.22 M(-58.2%) | $29.39 M(+78.5%) |
Sept 2008 | - | $16.46 M(-21.0%) |
June 2008 | - | $20.85 M(-7.4%) |
Mar 2008 | - | $22.51 M(-82.6%) |
Dec 2007 | $213.47 M(+39.9%) | $129.13 M(+339.7%) |
Sept 2007 | - | $29.37 M(+6.4%) |
June 2007 | - | $27.60 M(+0.8%) |
Mar 2007 | - | $27.38 M(+6.5%) |
Dec 2006 | $152.55 M(+2.4%) | $25.70 M(-37.7%) |
Sept 2006 | - | $41.27 M(+7.2%) |
June 2006 | - | $38.51 M(-18.2%) |
Mar 2006 | - | $47.07 M(+21.6%) |
Dec 2005 | $148.96 M(+8.3%) | $38.70 M(-2.3%) |
Sept 2005 | - | $39.62 M(+0.5%) |
June 2005 | - | $39.42 M(+26.3%) |
Mar 2005 | - | $31.21 M(-21.3%) |
Dec 2004 | $137.51 M(-30.5%) | $39.67 M(+5.1%) |
Sept 2004 | - | $37.73 M(+32.7%) |
June 2004 | - | $28.44 M(-10.2%) |
Mar 2004 | - | $31.67 M(-28.8%) |
Dec 2003 | $197.87 M(+62.6%) | $44.51 M(+3.9%) |
Sept 2003 | - | $42.83 M(-25.5%) |
June 2003 | - | $57.46 M(+8.3%) |
Mar 2003 | - | $53.07 M(+17.5%) |
Dec 2002 | $121.66 M(+42.9%) | $45.15 M(+64.3%) |
Sept 2002 | - | $27.48 M(+4.7%) |
June 2002 | - | $26.25 M(+15.2%) |
Mar 2002 | - | $22.78 M(-19.3%) |
Dec 2001 | $85.12 M(+62.5%) | $28.24 M(+38.4%) |
Sept 2001 | - | $20.40 M(+7.8%) |
June 2001 | - | $18.92 M(+7.7%) |
Mar 2001 | - | $17.57 M(+13.8%) |
Dec 2000 | $52.39 M(+35.0%) | $15.44 M(-0.9%) |
Sept 2000 | - | $15.57 M(+43.4%) |
June 2000 | - | $10.86 M(+3.2%) |
Mar 2000 | - | $10.52 M(+7.4%) |
Dec 1999 | $38.80 M(+28.9%) | $9.80 M(-8.4%) |
Sept 1999 | - | $10.70 M(+12.6%) |
June 1999 | - | $9.50 M(+9.2%) |
Mar 1999 | - | $8.70 M(+1.2%) |
Dec 1998 | $30.10 M(+11.9%) | $8.60 M(-1.1%) |
Sept 1998 | - | $8.70 M(+42.6%) |
June 1998 | - | $6.10 M(-11.6%) |
Mar 1998 | - | $6.90 M(-12.7%) |
Dec 1997 | $26.90 M(+55.5%) | $7.90 M(+14.5%) |
Sept 1997 | - | $6.90 M(+15.0%) |
June 1997 | - | $6.00 M(+1.7%) |
Mar 1997 | - | $5.90 M(-6.3%) |
Dec 1996 | $17.30 M | $6.30 M(+57.5%) |
Sept 1996 | - | $4.00 M(-9.1%) |
June 1996 | - | $4.40 M(+69.2%) |
Mar 1996 | - | $2.60 M |
FAQ
- What is Neurocrine Biosciences annual total operating expenses?
- What is the all time high annual operating expenses for Neurocrine Biosciences?
- What is Neurocrine Biosciences quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Neurocrine Biosciences?
- What is Neurocrine Biosciences quarterly operating expenses year-on-year change?
What is Neurocrine Biosciences annual total operating expenses?
The current annual operating expenses of NBIX is $1.45 B
What is the all time high annual operating expenses for Neurocrine Biosciences?
Neurocrine Biosciences all-time high annual total operating expenses is $1.45 B
What is Neurocrine Biosciences quarterly total operating expenses?
The current quarterly operating expenses of NBIX is $429.30 M
What is the all time high quarterly operating expenses for Neurocrine Biosciences?
Neurocrine Biosciences all-time high quarterly total operating expenses is $433.10 M
What is Neurocrine Biosciences quarterly operating expenses year-on-year change?
Over the past year, NBIX quarterly total operating expenses has changed by +$72.90 M (+20.45%)